Amneal Has The Firepower To Pursue Injectables Deals

With integration of the merger between Amneal and Impax largely completed, the US-focused group is on the look-out for deals to boost its generic injectables portfolio.

Vials
Amneal is looking to bolster its US injectables offering through business-development deals • Source: Shutterstock

Making tuck-in acquisitions to bolster its injectables portfolio, as well as looking for deals that would add to its Specialty salesforce’s bag in central nervous system (CNS) indications such as neurology, is a priority for Amneal, even as the US-based player looks to pay off debt and finalize integration measures.

Discussing business-development priorities with investors, president and chief executive officer Rob Stewart insisted that “we still do have some firepower”...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Deals

More from Business